This Small-Cap Pharma Expects 3 Late-Stage Data Readouts Soon
There's a possibility that Axsome Therapeutics (NASDAQ: AXSM) will transition into commercial operations in the same manner it arrived on investors' radars: overnight.
After beginning the year with a market valuation of just $79 million, the now-$1 billion pharmaceutical company expects to announce topline results from three phase 3 clinical trials and one phase 2 clinical trial before the end of 2019. The four research studies include three different pipeline assets aimed at treating four different disorders.
Successful results aren't guaranteed, of course, but Axsome Therapeutics is poised to have one heck of an end to the year, for better or for worse. Given the simplicity of the drug candidate formulations and the specific disorders being targeted, investors with a long-term mindset shouldn't necessarily think the stock can't go higher just because of its epic year-to-date performance.
Source Fool.com
